Company intelligence / Profile preview

GT Molecular

Fort Collins, Colorado, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

GT Molecular’s assays are clinically validated and commercially deployed, notably recognized as the first US lab to identify the SARS-CoV-2 UK variant in wastewater and received a CDC contract for multi-pathogen assay development[2][1].

Therapeutic areas: OncologyInfectious DiseasesOther
Modalities: Digital PCR assayQuantitative PCR assayNext-generation sequencing assayMolecular assay (general)
Industry: Molecular Diagnostics

Partnerships

Awarded multi-pathogen assay development contract by CDC; other R&D or supply partners not publicly named[2]

Beyond the preview

Go deeper on GT Molecular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT Molecular.

Explore the full profile